Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib with Chemotherapy in First-Line Non-Squamous NSCLC
NCT04012619Phase 1Completed
- Sponsor
- Sichuan University
- Start
- Apr 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anlotinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Sichuan University. Primary endpoint: Maximum Tolerated Dose at 1 month. Started Apr 2019; status: completed.
02
Drugs
anlotinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT04012619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04012619.